The Scandinavian-based drug development company Lytix Biopharma announced its intention to take its lead ultra-broad spectrum antimicrobial through to clinical trials. Broadly effective through rapid and selective cell lysis against even highly resistant bacterial strains such as MRSA, this novel class of small molecules exhibits an extremely low propensity for resistance development.
According to Lytix Biopharma CEO Øystein Rekdal, extensive preclinical studies have documented excellent efficacy for topical treatment: “Animal skin infection studies at the State Serum Institute in Copenhagen showed outstanding efficacy against Gram positive bacteria. Indeed, complete eradication of the test organism was obtained within 24 hours, considered vastly superior to Gold Standard treatments. Additional data shows that our lead compound has an unusually broad efficacy spectrum, including the Gram negative Pseudomonas species as well as yeasts and fungi. Toxicology and formulation work is already underway and we expect to able to submit our IND in the beginning of 2009. We have now chosen to partner with SAFC Pharma for the production of our lead compound in support of clinical trials.”